Biomarkers to Predict and Monitor Response to Infliximab

Status unconfirmed

Conditions studied: Crohn Disease

In brief

The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a prolonged response to Infliximab so that personalized medicine can be applied to patients with CD.

Key facts

Study ID

NCT04655729

Run by

Massachusetts General Hospital

People needed

120

Starts

2019-11-18

Expected to finish

2023-01-01

Last updated by the study team

2022-04-13

Who can join

Age: 3 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients between the ages of 3-20 years old
• Patient starting infliximab or infliximab biosimilar,
• Patients naïve to TNF inhibitor

You may not qualify if…

• Patients receiving infliximab or biosimilar infusions at home
• Patients already undergone significant bowel surgery relating to their Crohn's.

Where it is running

• MassGeneral for Children — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.